



## **GW Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference**

June 2, 2020

LONDON and CARLSBAD, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW's Chief Executive Officer, will present a business update at the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10th, 2020 at 1:20pm EDT, which is being held virtually.

A live audio webcast of the presentation will be available through GW's corporate website at [www.gwpharm.com](http://www.gwpharm.com) in the Investors section under Events & Presentations. A replay will be available soon after the live presentation.

### **About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.**

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX® (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older. This product has received approval in the European Union under the tradename EPIDYOLEX®. The Company has submitted applications in both the U.S. and Europe to expand the indication for Epidiolex to include seizures associated with Tuberous Sclerosis Complex (TSC), for which it has reported positive Phase 3 data, and is carrying out a Phase 3 trial in Rett syndrome. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury, as well as for the treatment of PTSD. The Company has additional cannabinoid product candidates in Phase 2 trials for autism and schizophrenia. For further information, please visit [www.gwpharm.com](http://www.gwpharm.com).

### **Enquiries:**

#### **GW Pharmaceuticals plc**

Stephen Schultz, VP Investor Relations 917 280 2424 / 401 500 6570  
(U.S.)